Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. - Zandberg, Dan P.; Algazi, Alain P.; Jimeno, Antonio; Good, James S.; Fayette, Jérôme; Bouganim, Nathaniel; Ready, Neal E.; Clement, Paul M.; Even, Caroline; Jang, Raymond W.; Wong, Stuart; Keilholz, Ulrich; et al. (European Journal of Cancer, 2019)